Hengrui Pharma(SH:600276) Shang Hai Zheng Quan Bao·2025-10-27 20:31Core Viewpoint - Heng Rui Medicine reported strong financial performance for the first three quarters of 2025, with revenue of 23.188 billion yuan, a year-on-year increase of 14.85%, and a net profit attributable to shareholders of 5.751 billion yuan, up 24.50% [2] Group 1: Financial Performance - The company achieved a revenue of 23.188 billion yuan in the first three quarters, reflecting a growth of 14.85% year-on-year [2] - The net profit attributable to shareholders reached 5.751 billion yuan, representing a 24.50% increase compared to the previous year [2] Group 2: R&D and Innovation - Research and development (R&D) expenses for the first three quarters amounted to 4.945 billion yuan, with cumulative R&D investment exceeding 50 billion yuan [3] - The company has successfully launched several innovative products, including the first domestically developed EZH2 inhibitor for relapsed or refractory peripheral T-cell lymphoma and a combination oral diabetes medication [3][4] - Heng Rui Medicine has received approval for 24 class 1 innovative drugs and 5 class 2 new drugs in China [3] Group 3: Internationalization Efforts - The company has accelerated its internationalization process, with significant collaborations announced, including a partnership with GSK to develop up to 12 innovative drugs, with an initial payment of 500 million USD and potential total payments of around 12 billion USD [4] - Heng Rui Medicine has initiated over 20 overseas clinical trials in regions such as the US, Europe, Australia, Japan, and South Korea [5] - The company has received orphan drug designation from the FDA for its innovative drug SHR-A1811 in combination with SHR-1316 for gastric cancer [5]